{"title":"密集剂量多西他赛与每周紫杉醇在密集剂量表柔比星和环磷酰胺辅助化疗后的对比:一项回顾性队列分析。","authors":"Sara Khoshroo, Saleh Sandoughdaran, Parisa Sabetrasekh, Parastoo Hajian, Pegah Bikdeli, Parto Sabetrasekh, Fatemeh Nasrollahi, Ladan Mohammadi Yeganeh, Sepideh Jafari Naeini, Hamid Reza Mirzaei","doi":"10.1155/2021/6653265","DOIUrl":null,"url":null,"abstract":"<p><strong>Methods: </strong>This study included patients from two prospective studies conducted in our institute from April 2007 to March 2009. Ninety-one women with axillary lymph node-positive breast cancer who had received four cycles of dose-dense epirubicin and cyclophosphamide were treated with either weekly paclitaxel (80 mg/m<sup>2</sup>) for 12 doses or biweekly docetaxel (75 mg/m<sup>2</sup>) for four cycles.</p><p><strong>Results: </strong>After a median follow-up of 88 and 109 months, 11 (23.4%) and 10 (22.7%) patients had experienced disease recurrence (<i>p</i> = 0.16), while 10 (21.3%) and 5 (11.4%) patients had died in the paclitaxel and docetaxel arm, respectively (<i>p</i> = 0.56). No significant difference could be seen in 5-year DFS or OS among groups (HR: 0.58; 95% CI: 0.19-1.81, <i>p</i> = 0.35; HR: 0.58; 95% CI: 0.19-1.81, <i>p</i> = 0.35, respectively).</p><p><strong>Conclusion: </strong>In conclusion, both evaluated adjuvant chemotherapy regimens have comparable effectiveness regarding DFS and OS.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2021-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478594/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis.\",\"authors\":\"Sara Khoshroo, Saleh Sandoughdaran, Parisa Sabetrasekh, Parastoo Hajian, Pegah Bikdeli, Parto Sabetrasekh, Fatemeh Nasrollahi, Ladan Mohammadi Yeganeh, Sepideh Jafari Naeini, Hamid Reza Mirzaei\",\"doi\":\"10.1155/2021/6653265\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Methods: </strong>This study included patients from two prospective studies conducted in our institute from April 2007 to March 2009. Ninety-one women with axillary lymph node-positive breast cancer who had received four cycles of dose-dense epirubicin and cyclophosphamide were treated with either weekly paclitaxel (80 mg/m<sup>2</sup>) for 12 doses or biweekly docetaxel (75 mg/m<sup>2</sup>) for four cycles.</p><p><strong>Results: </strong>After a median follow-up of 88 and 109 months, 11 (23.4%) and 10 (22.7%) patients had experienced disease recurrence (<i>p</i> = 0.16), while 10 (21.3%) and 5 (11.4%) patients had died in the paclitaxel and docetaxel arm, respectively (<i>p</i> = 0.56). No significant difference could be seen in 5-year DFS or OS among groups (HR: 0.58; 95% CI: 0.19-1.81, <i>p</i> = 0.35; HR: 0.58; 95% CI: 0.19-1.81, <i>p</i> = 0.35, respectively).</p><p><strong>Conclusion: </strong>In conclusion, both evaluated adjuvant chemotherapy regimens have comparable effectiveness regarding DFS and OS.</p>\",\"PeriodicalId\":46159,\"journal\":{\"name\":\"International Journal of Breast Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2021-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478594/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Breast Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/6653265\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/6653265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
方法:本研究纳入2007年4月至2009年3月在我院进行的两项前瞻性研究的患者。91名腋窝淋巴结阳性乳腺癌妇女接受了4个周期的剂量密集的表柔比星和环磷酰胺治疗,并接受每周紫杉醇(80 mg/m2)治疗12次或双周多西紫杉醇(75 mg/m2)治疗4次。结果:中位随访88个月和109个月后,紫杉醇组和多西紫杉醇组分别有11例(23.4%)和10例(22.7%)患者复发(p = 0.16),分别有10例(21.3%)和5例(11.4%)患者死亡(p = 0.56)。5年DFS和OS组间差异无统计学意义(HR: 0.58;95% CI: 0.19-1.81, p = 0.35;人力资源:0.58;95% CI: 0.19-1.81, p = 0.35)。结论:两种评估的辅助化疗方案在DFS和OS方面具有相当的有效性。
Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis.
Methods: This study included patients from two prospective studies conducted in our institute from April 2007 to March 2009. Ninety-one women with axillary lymph node-positive breast cancer who had received four cycles of dose-dense epirubicin and cyclophosphamide were treated with either weekly paclitaxel (80 mg/m2) for 12 doses or biweekly docetaxel (75 mg/m2) for four cycles.
Results: After a median follow-up of 88 and 109 months, 11 (23.4%) and 10 (22.7%) patients had experienced disease recurrence (p = 0.16), while 10 (21.3%) and 5 (11.4%) patients had died in the paclitaxel and docetaxel arm, respectively (p = 0.56). No significant difference could be seen in 5-year DFS or OS among groups (HR: 0.58; 95% CI: 0.19-1.81, p = 0.35; HR: 0.58; 95% CI: 0.19-1.81, p = 0.35, respectively).
Conclusion: In conclusion, both evaluated adjuvant chemotherapy regimens have comparable effectiveness regarding DFS and OS.
期刊介绍:
International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.